Verification register Bio, Health & Neuro
Current reading
The readiness gap, in one scan
AI-assisted assembly · derived results
- Claimed
- 25
- Reported
- 21
- Verified
- 14
- Gap
- +11
Public ambition and stated capability
Observed practitioner reporting
Independently supported evidence
Claimed minus verified
Evidence strength Growing
Decision
What the current evidence supports
Human editorial judgment · 2026-06-28
Too early to adopt
- Why
- Dual-regulator IND clearance and reputable trial sites are credible milestones, but the asset is at first-patient-dosed with all efficacy evidence still in mice; primary sources are company press releases. No real-world clinical signal to evaluate yet.
- Next
- Re-check in 2026 for the Phase I monotherapy dose-escalation safety/tolerability readout and any anti-PD-1 combination data before forming a maturity view.
Constraints
Blockers
No named blocker is present in the current public projection.
Evidence summary
Derived counts
AI-assisted assembly
- Total
- 6
- Tier 1
- 4
- Tier 2
- 2
- Tier 3
- 0
- Supports
- 2
- Contradicts
- 2
- Context
- 2
- Latest observed
- 2025-11-21
Counts and dates only. Raw signals, private excerpts, trust records, and internal corpus material are not published here.
Publication record
Revisions
Initial public reading
This is the initial public reading. No earlier readiness change is recorded.